American Association for Cancer Research
00085472can173754-sup-193467_3_supp_4845132_p1p11t.pdf (5.13 MB)

Figure S2 from Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy

Download (5.13 MB)
journal contribution
posted on 2023-03-31, 03:44 authored by Teresa Cejalvo, Ana Judith Perisé-Barrios, Isabel del Portillo, Eduardo Laborda, Miguel A. Rodriguez-Milla, Isabel Cubillo, Fernando Vázquez, David Sardón, Manuel Ramirez, Ramon Alemany, Noemí del Castillo, Javier García-Castro

Clinical and anatomo-pathological results in canine patients treated with dCelyvir.


Fondo de Investigaciones Sanitarias

Madrid Regional Government

Asociación Pablo Ugarte



Dogs with spontaneous tumors treated in veterinary hospitals offer an excellent opportunity for studying immunotherapies, including oncolytic viruses. Oncolytic viruses have advanced into the clinic as an intratumorally administered therapeutic; however, intravenous delivery has been hindered by neutralization in the blood. To circumvent this hurdle, mesenchymal stem cells have been used as a "Trojan horse." Here, we present the treatment of 27 canine patients with cancer with canine mesenchymal stem cells infected with ICOCAV17, a canine oncolytic adenovirus. No significant adverse effects were found. The response rate was 74%, with 14.8% showing complete responses, including total remissions of lung metastasis. We detected virus infection, stromal degeneration, and immune cell infiltration in tumor biopsies after 4 weeks of treatment. The increased presence of antiadenoviral antibodies in the peripheral blood of treated dogs did not appear to prevent the clinical benefit of this therapy. These data indicate that oncolytic viruses loaded in mesenchymal stem cells represent an effective cancer immunotherapy.Significance: The classical clinical limitations of antitumoral viroimmunotherapy can be overcome by use of mesenchymal stem cells.Graphical Abstract: Cancer Res; 78(17); 4891–901. ©2018 AACR.